Blood Clot Prevention Study in Myeloma Patients
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study looks at how blood thinners are used in people with newly diagnosed multiple myeloma. The goal is to find better ways to prevent blood clots during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a new diagnosis of multiple myeloma that is causing symptoms or other problems.
- You must be about to start your very first treatment for myeloma.
- You must not have had a blood clot in the 6 months before your myeloma diagnosis.
- You cannot already be taking a combination of blood thinners and antiplatelet drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at bleeding risks in people newly diagnosed with multiple myeloma who are taking blood thinners (aspirin or a low-molecular-weight heparin). You'll fill out a few questionnaires to help doctors learn how to better prevent bleeding.
This trial is testing whether aspirin or a blood thinner called rivaroxaban can best prevent harmful blood clots in people newly diagnosed with multiple myeloma who have a high risk of developing clots. It aims to find a safer and more effective way to protect you during treatment.
This study looks at how Apixaban (a blood thinner) works in people with newly diagnosed multiple myeloma. It compares them to people having knee replacement surgery. The goal is to see if the drug prevents clots effectively in both groups.
This trial studies myeloma (and closely related blood disorders) by using extra blood or bone marrow samples for lab research. It aims to help discover new ways to understand or treat myeloma.
This trial tests a new treatment for people with newly diagnosed multiple myeloma that has not been treated before. It looks at whether adding a targeted therapy to standard treatment helps control the disease better.
This trial screens first-degree relatives of people with multiple myeloma to check for early signs of the disease before symptoms. It may help doctors understand risk in families and find problems sooner if they occur.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.